CCDC74B

Across TCGA pan-cancer cohorts, CCDC74B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC74B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCDC74B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC74B expression acts as an unfavorable survival marker.

BLCA, SKCM, and LUAD are the cancer types where CCDC74B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.090	0.655	<.001	12	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	8	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC74B–BLCA (OS)

Open the BLCA breakdown →